Shots:

• The P-III ASCEND study involves assessing of Calquence (acalabrutinib- 100mg- q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL
• The P-III ASCEND study resulted in meeting its 1EPs i.e- improvement in progression-free survival (PFS)- increment in the time for the next treatment and is safe & tolerable
• Calquence (acalabrutinib) is a BTK inhibitor- inhibiting its activity in B-cells- currently being evaluated in 26 studies by AstraZeneca & Acerta Pharma and has received FDA’s accelerated approval for MCL with one prior therapy in Oct’17  

Ref: AstraZeneca | Image: AstraZeneca